Drugs / CC-90001
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04655898 | Dec 2020 → Mar 2021 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03958864 | Apr → Jun 2019 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03742882 | Dec 2018 → Jun 2019 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03363815 | Dec 2017 → Jul 2018 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02510937 | Aug 2015 → Feb 2017 | pulmonary fibrosis | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02321644 | Nov 2014 → Feb 2015 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02110420 | Feb → Sep 2014 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04048876 | Aug 2019 → Sep 2021 | NAFLD1, cirrhosis of liver | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03142191 | Jul 2017 → Dec 2021 | idiopathic pulmonary fibrosis, pulmonary fibrosis | Celgene Corporation | Terminated | Missed primary Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-90001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02510937 ↗ |
| Action | Inhibit | “CC-90001 is a potent, selective inhibitor of JNK.” NCT03142191 ↗ |
| Modality | Small molecule | — CHEMBL4847106 ↗ |
| Route | Oral | “CC-90001 480mg will be administered as a single oral dose” NCT02110420 ↗ |